Myeloma

Blood Cancers

Brain Cancer

Metastatic Breast Cancer

Breast Cancer

Childhood Cancers

Colorectal Cancer

Esophageal Cancer

Gastrointestinal stromal tumor

Liver Cancer

Pancreatic Cancer

Gastrointestinal Cancers

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancers

Cervical Cancer

Ovarian Cancer

Gynecologic Cancer

Head & Neck Cancer

Acute Myeloid Leukemia

Leukemia

Lung Cancer

Follicular Lymphoma

Mantle Cell Lymphoma

Non-Hodgkin Lymphoma

Lymphoma

Neuroendocrine Cancer

Rare Cancers

Sarcoma

Skin Cancer/Melanoma

Thyroid Cancer

News

Cancer Horizons

All News

Blogs

Caregiving

Diet and Exercise

Financial

Psychosocial

Recipes

Sexual Health

Side Effect

Survivorship

Videos

All Videos

CURE Connections

CURE Expert Connections®

CURE Speaking Out

CURE TV

Educated Patient Sound Bites

On Demand: Webinars

Conferences

Conference Coverage 

Conference Listing 

Events

CURE Adventures

CURE Awards

Educated Patient In Person Education

Educated Patient Virtual Education

Resources

Advocacy Groups

Art Gallery

Clinical Trial Corner

Heal®

Partners

Podcasts

Publications

Share Your Story

Subscribe

CURE connects oncology patients, survivors, and caregivers with expert guidance, cancer updates, treatment education, and clinical trial access.

About Us

Advertise / Support

Editorial Board

Contact Us

CancerNetwork.com

TargetedOnc.com

OncLive.com

OncNursingNews.com

Terms & Conditions

Privacy

Do Not Sell My Information

CURE - Oncology & Cancer News for Patients & Caregivers

Facebook

Youtube

Instagram

Spotlight

Breast Cancer Webinar Series

Cancer Type

Bladder

Breast

Kidney

Lung

Ovarian

Prostate

Skin

About CURE

Press Releases

Write for CURE

1rem

View

Updates in Diagnosis, Treatment, and Management of Metastatic Uveal Melanoma

CURE Expert Connections

Sunandana Chandra, MD, MS, delves into the evolution of the metastatic uveal melanoma treatment landscape and the discussions she has with patients during treatment decision-making.

Editor's note: Tebentafusp is pronounced “teh-BEN-tah-fuhsp.”

Sunandana Chandra, MD, MS, explains how uveal melanoma is different from cutaneous melanoma, including prevalence, molecular mutations, and survival prognosis after metastasis.

How Uveal Melanoma Differs from Cutaneous Melanoma

Dr Sunandana Chandra describes the typical symptoms that patients with uveal melanoma experience, the prevalent asymptomatic patient population, and how optometrists and ophthalmologists may be involved in the diagnostic process.

Common Symptoms of Uveal Melanoma and the Typical Diagnostic Journey of the Patient

An expert provides an overview of the historical and currently available treatment options in metastatic uveal melanoma (mUM), including the bispecific T-cell receptor immunotherapy tebentafusp (“teh-BEN-tah-fuhsp”).

Historic and Current Treatment Options for mUM

Sunandana Chandra, MD, MS, discusses safety and efficacy data from the IMCgp100-202 trial on tebentafusp, and comments on the clinical implications of these data.

Implications of Clinical Trial Data on Bispecific T-Cell Receptor Immunotherapy for mUM

An oncologist outlines which patients with mUM are eligible for bispecific T-cell receptor immunotherapy, discusses logistical and safety considerations, and explains why pre-treatment HLA testing is required for those considering the regimen.

Patient Eligibility and Logistical and Safety Considerations for Tebentafusp Treatment in mUM

Dr Sunandana Chandra highlights her personal experience in prescribing tebentafusp and other therapies for mUM, and discusses the educational resources and advocacy organizations that she encourages patients to look into to help make an informed decision about their treatment regimens.

An Expert’s Experience in Prescribing Tebentafusp and Other Therapies for mUM and a Commentary on Patient Education and Resources

An overview of the treatment options for patients with mUM who ineligible for treatment with tebentafusp.

Treatment Options for Patients with mUM Who Are Ineligible for Bispecific T-Cell Receptor Immunotherapy

Sunandana Chandra, MD, MS, closes by sharing advice for patients with metastatic uveal melanoma.

Advice for Patients Living with Metastatic Uveal Melanoma

CURE Expert Connections® is a video series designed to help patients and their loved ones along their cancer care journey by offering information and expert advice from leaders in oncology care. Expert medical professionals share their knowledge and insights on an array of topics to allow for a better understanding of what to expect following a cancer diagnosis. Expert Connections hopes to bridge the gap between patients and oncology professionals to ensure no question is left unanswered.

Treatment Options for Patients with mUM Who Are Ineligible for Bispecific T-Cell Receptor Immunotherapy

EP: 1.How Uveal Melanoma Differs from Cutaneous Melanoma

EP: 2.Common Symptoms of Uveal Melanoma and the Typical Diagnostic Journey of the Patient

EP: 3.Historic and Current Treatment Options for mUM

EP: 4.Implications of Clinical Trial Data on Bispecific T-Cell Receptor Immunotherapy for mUM

EP: 5.Patient Eligibility and Logistical and Safety Considerations for Tebentafusp Treatment in mUM

EP: 6.An Expert’s Experience in Prescribing Tebentafusp and Other Therapies for mUM and a Commentary on Patient Education and Resources

EP: 7.Treatment Options for Patients with mUM Who Are Ineligible for Bispecific T-Cell Receptor Immunotherapy

EP: 8.Advice for Patients Living with Metastatic Uveal Melanoma

Newsletter